The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass
an annual incidence of 1 million cases. Genomic studies have established the landscape of …

Hepatocellular carcinoma (HCC) arises from hepatocytes through the sequential
accumulation of multiple genomic and epigenomic alterations resulting from Darwinian …

Organoid models have the potential to recapitulate the biological and pharmacotypic
features of parental tumors. Nevertheless, integrative pharmaco-proteogenomics analysis …

Hepatocellular carcinoma (HCC) is one of the main cancer-related causes of death
worldwide. Thus, there is a constant search for improvement in screening, diagnosis, and …

There is great geographical variation in the distribution of hepatocellular carcinoma (HCC),
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …

Evidence-based management of patients with hepatocellular carcinoma (HCC) is key to
their optimal care. For individuals at risk for HCC, surveillance usually involves …

Hepatocellular carcinoma (HCC) is a complex biological process and is often diagnosed at
advanced stages with no effective treatment options. With advances in tumor biology and …

Background Cabozantinib is an oral inhibitor of tyrosine kinases including MET, VEGFR,
and AXL. The randomised phase 3 METEOR trial compared the efficacy and safety of …

Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …